ASCO Rally Fades But Spec Stocks Rock: FCSC,RXDX
ASCO Week in Review- Rayno Biopharmaceutical Stocks The market action over the past week focused on speculative stocks rather than the overall biopharmaceutical sector. Major ETFs over five days were mixed with the smaller cap XBI up over 1%, the IBB flat and the FBT trailed down 0.7%. Many of...
ASCO 2015 Biotech Movers Day Two: FCSC, JUNO, RXDX
Update-1 BLUE Drops 1.96% and 1.77% After Hours 6/3 In the bubbly CAR-T world bluebird bio (BLUE) and Celgene announced a deal for for development of product candidates for B-cell maturation antigen (BMCA) utilizing bluebird bios’s gene therapy technology to modify a patient’s own...
Rayno Biopharma Stocks at ASCO: ARRY, CLVS, RXDX
Biotech Indices Can’t Break Through Triple Top IBB at $365, XBI at $239 Red and green day Biotech stocks were mixed today with the major indices holding the flat line. However with all of the clinical data coming out of ASCO (American Society for Clinical Oncology) 2015 in Chicago, IL...
Biotech (IBB) 2015 Triple Top Is Here ! NASDAQ Hits New High…Update
Update-1 Mixed Market but CAR-T stocks soar Biotechs could not break through the top today and were down about 0.5%. The XBI and XLV did a little better almost flat. Red and green were just about mixed among many stocks. Biomarin (BMRN) a “rare disease” mid-cap stock was down 1.66%...
Regulatory News for Rare Disease Products-Hot Stocks: BLUE,ICPT,SRPT …Updates
Update-2 uniQure up on deal with BMY (CURE) Cardiovascular Deal with Bristol Myers (BMY) The closing of the uniQure deal with Bristol Myers triggered a $50M payment. Three collaboration targets in cardiovascular and future areas. The stock is up 81% YTD but off its high of $35.50. Update-1 See...